The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Antibiotic treatment for Clostridium difficile -associated diarrhoea in adults
Open accessAbstract
BACKGROUND: Clostridium difficile (C. difficile) is recognized as a frequent cause of antibiotic-associated diarrhoea and colitis. This review is an update of a previously published Cochrane review. OBJECTIVES: The aim of this review is to investigate the efficacy and safety of antibiotic therapy for C. difficile-associated diarrhoea (CDAD), or C. difficile infection (CDI), being synonymous terms. SEARCH METHODS: We searched MEDLINE, EMBASE, CENTRAL and the Cochrane IBD Group Specialized Trials Register from inception to 26 January 2017. We also searched clinicaltrials.gov and clinicaltrialsregister.eu for ongoing trials. SELECTION CRITERIA: Only randomised controlled trials assessing antibiotic treatment for CDI were included in the review. DATA COLLECTION AND ANALYSIS: Three authors independently assessed abstracts and full text articles for inclusion and extracted data. The risk of bias was independently rated by two authors. For dichotomous outcomes, we calculated the risk ratio (RR) and corresponding 95% confidence interval (95% CI). We pooled data using a fixed-effect model, except where significant heterogeneity was detected, at which time a random-effects model was used. The following outcomes were sought: sustained symptomatic cure (defined as initial symptomatic response and no recurrence of CDI), sustained bacteriologic cure, adverse reactions to the intervention, death and cost. MAIN RESULTS: Twenty-two studies (3215 participants) were included. The majority of studies enrolled patients with mild to moderate CDI who could tolerate oral antibiotics. Sixteen of the included studies excluded patients with severe CDI and few patients with severe CDI were included in the other six studies. Twelve different antibiotics were investigated: vancomycin, metronidazole, fusidic acid, nitazoxanide, teicoplanin, rifampin, rifaximin, bacitracin, cadazolid, LFF517, surotomycin and fidaxomicin. Most of the studies were active comparator studies comparing vancomycin with other antibiotics. One small study compared vancomycin to placebo. There were no other studies that compared antibiotic treatment to a placebo or a 'no treatment' control group. The risk of bias was rated as high for 17 of 22 included studies. Vancomycin was found to be more effective than metronidazole for achieving symptomatic cure. Seventy-two per cent (318/444) of metronidazole patients achieved symptomatic cure compared to 79% (339/428) of vancomycin patients (RR 0.90, 95% CI 0.84 to 0.97; moderate quality evidence). Fidaxomicin was found to be more effective than vancomycin for achieving symptomatic cure. Seventy-one per cent (407/572) of fidaxomicin patients achieved symptomatic cure compared to 61% (361/592) of vancomycin patients (RR 1.17, 95% CI 1.04 to 1.31; moderate quality evidence). Teicoplanin may be more effective than vancomycin for achieving a symptomatic cure. Eightly-seven per cent (48/55) of teicoplanin patients achieved symptomatic cure compared to 73% (40/55) of vancomycin patients (RR 1.21, 95% CI 1.00 to 1.46; very low quality evidence). For other comparisons including the one placebo-controlled study the quality of evidence was low or very low due to imprecision and in many cases high risk of bias because of attrition and lack of blinding. One hundred and forty deaths were reported in the studies, all of which were attributed by study authors to the co-morbidities of the participants that lead to acquiring CDI. Although many other adverse events were reported during therapy, these were attributed to the participants' co-morbidities. The only adverse events directly attributed to study medication were rare nausea and transient elevation of liver enzymes. Recent cost data (July 2016) for a 10 day course of treatment shows that metronidazole 500 mg is the least expensive antibiotic with a cost of USD 13 (Health Warehouse). Vancomycin 125 mg costs USD 1779 (Walgreens for 56 tablets) compared to fidaxomicin 200 mg at USD 3453.83 or more (Optimer Pharmaceuticals) and teicoplanin at approximately USD 83.67 (GBP 71.40, British National Formulary). AUTHORS' CONCLUSIONS: No firm conclusions can be drawn regarding the efficacy of antibiotic treatment in severe CDI as most studies excluded patients with severe disease. The lack of any 'no treatment' control studies does not allow for any conclusions regarding the need for antibiotic treatment in patients with mild CDI beyond withdrawal of the initiating antibiotic. Nonetheless, moderate quality evidence suggests that vancomycin is superior to metronidazole and fidaxomicin is superior to vancomycin. The differences in effectiveness between these antibiotics were not too large and the advantage of metronidazole is its far lower cost compared to the other two antibiotics. The quality of evidence for teicoplanin is very low. Adequately powered studies are needed to determine if teicoplanin performs as well as the other antibiotics. A trial comparing the two cheapest antibiotics, metroni
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2008) · Cited by 3,790
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Burden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Kelly, C. P., Pothoulakis, C., & LaMont, J. T. (1994) · New England Journal of Medicine · doi:10.1056/nejm199401273300406 · Cited by 1,321
Zar, F. A., Bakkanagari, S. R., Moorthi, K. M. L. S. T., & Davis, M. B. (2007) · Clinical Infectious Diseases · doi:10.1086/519265 · Cited by 1,252
Antibiotic-Associated Diarrhea
Bartlett, J. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp011603 · Cited by 1,197
Subgroup analysis and other (mis)uses of baseline data in clinical trials
Assmann, S. F., Pocock, S. J., Enos, L. E., & Kasten, L. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02039-0 · Cited by 1,167
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Chapter 12: Interpreting results and drawing conclusions
Schünemann, H. J., Oxman, A. D., Jonathan, J., & Glasziou, P. (2011) · Cited by 870
Teasley, D., Olson, M., Gebhard, R., Gerding, D., Peterson, L., Schwartz, M., & Lee, J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91036-x · Cited by 785
Cornely, O. A., Crook, D. W., Esposito, R., Poirier, A., Somero, M. S., Weiss, K., Sears, P., & Gorbach, S. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70374-7 · Cited by 761
Treatment with Monoclonal Antibodies against Clostridium difficile Toxins
Lowy, I., Molrine, D. C., Leav, B. A., Blair, B. M., Baxter, R., Gerding, D. N., Nichol, G., Thomas, W. D., Leney, M., Sloan, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907635 · Cited by 746
Breaking The Cycle: Treatment Strategies for 163 Cases of Recurrent Clostridium Difficile Disease
McFarland, L. V., Elmer, G. W., & Surawicz, C. M. (2002) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05839.x · Cited by 724
(1995) · American Journal of Infection Control · doi:10.1016/0196-6553(95)90104-3 · Cited by 709
Khoruts, A., Dicksved, J., Jansson, J. K., & Sadowsky, M. J. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181c87e02 · Cited by 649
Clostridium Difficile-Associated Diarrhea and Colitis
Gerding, D. N., Johnson, S., Peterson, L. R., Mulligan, M. E., & Silva, J. (1995) · Infection Control & Hospital Epidemiology · doi:10.1086/648363 · Cited by 631
Lee, C. H., Steiner, T., Petrof, E. O., Smieja, M., Roscoe, D., Nematallah, A., Weese, J. S., Collins, S., Moayyedi, P., Crowther, M., et al. (2016) · JAMA · doi:10.1001/jama.2015.18098 · Cited by 627
Pepin, J. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.050978 · Cited by 606
Cammarota, G., Masucci, L., Ianiro, G., Bibbò, S., Dinoi, G., Costamagna, G., Sanguinetti, M., & Gasbarrini, A. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13144 · Cited by 558
Johnson, S., Louie, T. J., Gerding, D. N., Cornely, O. A., Chasan-Taber, S., Fitts, D., Gelone, S. P., Broom, C., Davidson, D. M., & for the Polymer Alternative for CDI Treatment (PACT) investigators (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu313 · Cited by 527
Wenisch, C., Parschalk, B., Hasenhundl, M., Hirschl, A. M., & Graninger, W. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.5.813 · Cited by 505
Diagnosis and Treatment of Clostridium difficile in Adults: A Systematic Review
Bagdasarian, N., Rao, K., & Malani, P. N. (2015) · JAMA · doi:10.1001/jama.2014.17103 · Cited by 451
Increase in Clostridium difficile–related Mortality Rates, United States, 1999–2004
Redelings, M. D., Sorvillo, F., & Mascola, L. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1309.061116 · Cited by 429
Clostridium difficile-Associated Diarrhea and Colitis
Gerding, D. N., Johnson, S., Peterson, L. R., Mulligan, M. E., & Silva, J. (1995) · Infection Control and Hospital Epidemiology · doi:10.2307/30141083 · Cited by 398
Bauer, M. P., Kuijper, E. J., & van Dissel, J. T. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03099.x · Cited by 366
Johnson, S., Homann, S. R., Bettin, K. M., Quick, J. N., Clabots, C. R., Peterson, L. R., & Gerding, D. N. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-297 · Cited by 355
Diagnosis and Treatment of Clostridium difficile Colitis
Fekety, R. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500010081036 · Cited by 354
Recurrent Clostridium Difficile Disease: Epidemiology and Clinical Characteristics
McFarland, L. V., Surawicz, C. M., Rubin, M., Fekety, R., Elmer, G. W., & Greenberg, R. N. (1999) · Infection Control & Hospital Epidemiology · doi:10.1086/501553 · Cited by 353
Olson, M. M., Shanholtzer, C. J., Lee, J. T., & Gerding, D. N. (1994) · Infection Control & Hospital Epidemiology · doi:10.1086/646934 · Cited by 339
Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo.
McFarland, L. V., Surawicz, C. M., Greenberg, R. N., Elmer, G. W., Moyer, K. A., Melcher, S. A., Bowen, K., & Cox, J. L. (1995) · PubMed · Cited by 338
Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review
Thomas, C. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg254 · Cited by 305
Fekety, R., Silva, J., Kauffman, C., Buggy, B., & Gunner Deery, H. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90223-4 · Cited by 293
Multiple hypothesis testing and Bonferroni's correction
Sedgwick, P. (2014) · BMJ · doi:10.1136/bmj.g6284 · Cited by 271
Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea
Sougioultzis, S., Kyne, L., Drudy, D., Keates, S., Maroo, S., Pothoulakis, C., Giannasca, P. J., Lee, C. K., Warny, M., Monath, T. P., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.004 · Cited by 260
Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea.
Keighley, M. R., Burdon, D. W., Arabi, Y., Williams, J. A., Thompson, H., Youngs, D., Johnson, M., Bentley, S., George, R. H., & Mogg, G. A. (1978) · BMJ · doi:10.1136/bmj.2.6153.1667 · Cited by 254
Vardakas, K. Z., Polyzos, K. A., Patouni, K., Rafailidis, P. I., Samonis, G., & Falagas, M. E. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.01.004 · Cited by 250
Nitazoxanide for the Treatment of Clostridium difficile Colitis
Musher, D. M., Logan, N., Hamill, R. J., DuPont, H. L., Lentnek, A., Gupta, A., & Rossignol, J.-F. (2006) · Clinical Infectious Diseases · doi:10.1086/506351 · Cited by 249
Clostridium difficile: Clinical Considerations
Bartlett, J. G. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_2.s243 · Cited by 209
Louie, T. J., Peppe, J., Watt, C. K., Johnson, D., Mohammed, R., Dow, G., Weiss, K., Simon, S., John, J. F., Garber, G., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/506349 · Cited by 203
Non-inferiority trials are unethical because they disregard patients' interests
Garattini, S., & Bertele', V. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61604-3 · Cited by 197
Nitazoxanide versus Vancomycin in Clostridium difficile Infection: A Randomized, Double‐Blind Study
Musher, D. M., Logan, N., Bressler, A. M., Johnson, D. P., & Rossignol, J. (2009) · Clinical Infectious Diseases · doi:10.1086/596552 · Cited by 186
Garey, K. W., Ghantoji, S. S., Shah, D. N., Habib, M., Arora, V., Jiang, Z.-D., & DuPont, H. L. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr377 · Cited by 181
Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis.
Bowden, T. A., Ar, M., & Le, L. (1981) · PubMed · Cited by 179
Young, G. P., Ward, P. B., Bayley, N., Gordon, D., Higgins, G., Trapani, J. A., McDonald, M. I., Labrooy, J., & Hecker, R. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90206-9 · Cited by 171
Clinical and laboratory observations in Clostridium difficile colitis
Bartlett, J. G., Taylor, N. S., Chang, T., & Dzink, J. (1980) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/33.11.2521 · Cited by 162
Privitera, G., Scarpellini, P., Ortisi, G., Nicastro, G., Nicolin, R., & de Lalla, F. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.1.208 · Cited by 162
A review of mortality due to Clostridium difficile infection
Karas, J. A., Enoch, D., & Aliyu, S. H. (2010) · Journal of Infection · doi:10.1016/j.jinf.2010.03.025 · Cited by 153
George, W. L., Rolfe, R. D., & Finegold, S. M. (1982) · Journal of Clinical Microbiology · doi:10.1128/jcm.15.6.1049-1053.1982 · Cited by 141
Comparative Effectiveness of Clostridium difficile Treatments: A Systematic Review
Drekonja, D. M., Butler, M. E., MacDonald, R. H., Bliss, D. Z., FILICE, G. A., Rector, T. S., & Wilt, T. J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-12-201112200-00007 · Cited by 140
Lagrotteria, D. D., Holmes, S., Smieja, M., Smaill, F., & Lee, C. (2006) · Clinical Infectious Diseases · doi:10.1086/506354 · Cited by 118
Baker, S. G., & Kramer, B. S. (2002) · BMC Medical Research Methodology · doi:10.1186/1471-2288-2-13 · Cited by 116
Morris, A. M., Jobe, B. A., Stoney, M., Sheppard, B. C., Deveney, C. W., & Deveney, K. E. (2002) · Archives of Surgery · doi:10.1001/archsurg.137.10.1096 · Cited by 115
Short, V. L., Totten, P. A., Ness, R. B., Astete, S. G., Kelsey, S. F., & Haggerty, C. L. (2008) · Clinical Infectious Diseases · doi:10.1086/594123 · Cited by 115
Louie, T., Miller, M., Donskey, C. J., Mullane, K. M., & Goldstein, E. J. C. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01442-07 · Cited by 112
Wullt, M. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh278 · Cited by 107
Lessons From and Cautions About Noninferiority and Equivalence Randomized Trials
Gøtzsche, P. C. (2006) · JAMA · doi:10.1001/jama.295.10.1172 · Cited by 106
Mullane, K. M., Lee, C., Bressler, A. M., Buitrago, M. I., Weiss, K., Dabovic, K., Præstgaard, J., Leeds, J. A., Blais, J., & Pertel, P. E. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04251-14 · Cited by 101
Stranges, P. M., Hutton, D. W., & Collins, C. D. (2013) · Value in Health · doi:10.1016/j.jval.2012.11.004 · Cited by 100
de Bruyn, G., Saleh, J., Workman, D., Pollak, R. A., Elinoff, V., Fraser, N. J., Lefebvre, G., Martens, M. G., Mills, R. E., Nathan, R., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.03.028 · Cited by 95
Is colectomy for fulminant Clostridium difficile colitis life saving? A systematic review
Stewart, D. B., Hollenbeak, C. S., & Wilson, M. Z. (2013) · Colorectal Disease · doi:10.1111/codi.12134 · Cited by 93
Clostridium Difficile-Associated Diarrhea: Epidemiology, Risk Factors, and Infection Control
Lai, K. K., Melvin, Z. S., Menard, M. J., Kotilainen, H. R., & Baker, S. P. (1997) · Infection Control and Hospital Epidemiology · doi:10.2307/30141489 · Cited by 85
Locher, H. H., Caspers, P., Bruyère, T., Schroeder, S., Pfaff, P., Knezevic, A., Keck, W., & Ritz, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01831-13 · Cited by 85
Mattila, E. J., Anttila, V.-J., Broas, M., Marttila, H., Poukka, P., Kuusisto, K., Pusa, L., Sammalkorpi, K., Dabek, J. T., Koivurova, O., et al. (2008) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540801964960 · Cited by 77
Louie, T., Nord, C. E., Talbot, G. H., Wilcox, M. H., Gerding, D. N., Buitrago, M. I., Kracker, H., Charef, P., & Cornely, O. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00504-15 · Cited by 76
Antibiotic treatment for Clostridium difficile-associated diarrhea in adults
Nelson, R. L. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004610.pub3 · Cited by 71
Self-citationNuman, S. C., Veldkamp, P. J., Kuijper, E. J., van den Berg, R. J., & van Dissel, J. T. (2007) · Gut · doi:10.1136/gut.2006.119016 · Cited by 57
Lee, C., Patino, H., Stevens, C., Rege, S., Chesnel, L., Louie, T., & Mullane, K. M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw246 · Cited by 52
Di, X., Bai, N., Zhang, X., Liu, B., Ni, W., Wang, J., Wang, K., Liang, B., Liu, Y.-N., & Wang, R. (2015) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2015.03.006 · Cited by 45
Antibiotic treatment forClostridium difficile-associated diarrhea in adults
Nelson, R. L., Kelsey, P., Leeman, H., Meardon, N., Patel, H., Paul, K., Rees, R. N., Taylor, B., Wood, E., & Malakun, R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004610.pub4 · Cited by 43
Self-citationGerding, D. N., Hecht, D. W., Louie, T., Nord, C. E., Talbot, G. H., Cornely, O. A., Buitrago, M. I., Best, E. L., Sambol, S. P., Osmolski, J. R., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv300 · Cited by 31
Effect of an antimicrobial stewardship bundle for patients withClostridium difficileinfection
Brumley, P. E., Malani, A. N., Kabara, J. J., Pisani, J., & Collins, C. D. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv404 · Cited by 30
Thabit, A. K., & Nicolau, D. P. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.03.016 · Cited by 27
Soonawala, D., Middelburg, R. A., Egger, M., Vandenbroucke, J. P., & Dekkers, O. M. (2010) · International Journal of Epidemiology · doi:10.1093/ije/dyq136 · Cited by 27
(1994) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365549409011800 · Cited by 27
Johnson, S., Gerding, D. N., Louie, T., Ruíz, N., & Gorbach, S. L. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00605-12 · Cited by 24
The Relationship between Inpatient Fluoroquinolone Use and Clostridium difficile-Associated Diarrhea
Novell, M. J., & Morreale, C. A. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m696 · Cited by 20
Fidaxomicin versus Vancomycin in the Treatment ofClostridium difficileInfection: Canadian Outcomes
Lee, C., Louie, T., Weiss, K., Valiquette, L., Gerson, M., Arnott, W., & Gorbach, S. L. (2016) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2016/8048757 · Cited by 20
Welch, H. K., Nagel, J. L., Patel, T. S., Gandhi, T. N., Chen, B., Leon, J. D., Chenoweth, C., Washer, L., Rao, K. K., & Eschenauer, G. A. (2016) · American Journal of Infection Control · doi:10.1016/j.ajic.2016.05.027 · Cited by 19
How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?
Louie, T. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.051212 · Cited by 16
Kaki, R., Brooks, A. A., Main, C. L., Jayaratne, P., & Mertz, D. (2016) · The Internet Journal of Infectious Diseases · Cited by 12
Barker, A., Duster, M. N., Valentine, S., Archbald‐Pannone, L. R., Guerrant, R. L., & Safdar, N. (2015) · Contemporary Clinical Trials · doi:10.1016/j.cct.2015.07.015 · Cited by 10
Quebec to report on Clostridium difficile in 2005
Pindera, L. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041435 · Cited by 9
Cited by
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Bacteriocins—A viable alternative to antibiotics?
Cotter, P. D., Ross, R. P., & Hill, C. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2937 · Cited by 1,793
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Debast, S. B., Bauer, M. P., & Kuijper, E. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12418 · Cited by 1,215
McFarland, L. V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00465.x · Cited by 872
Metadata
- Authors
- Nelson, R. L., Suda, K. J., & Evans, C. T.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-03-03
- Volume
- 2017
- Issue
- 3
- Pages
- CD004610-CD004610
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2166223093
- Cited by
- 366
- References
- 87
- FWCI
- 16.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.